Retosiban

CAS: 820957-38-8

Ref. 3D-VHB95738

Produktinformation

• Name: Retosiban
• Synonyme: (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-(4-morpholinyl)-2-oxoethyl]-6-((1S)-1-methylpropyl)-2,5-piperazinedione, Morpholine, 4-[(2R)-[(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl](2-methyl-4-oxazolyl)acetyl]-, 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)-, (3R,6R)-3-(2,3-Dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione

Beschreibung

Retosiban is a crystalline polymorph of atosiban, which is a cyclic peptidyl oxytocin receptor agonist. It has been shown to inhibit the release of oxytocin in human myometrial cells and can be used for the treatment of uterine contractions. Retosiban also has an inhibitory effect on the production of prostaglandins and collagenase activity, suggesting that it may have therapeutic potential in the treatment of cancer and autoimmune diseases.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 494.6 g/mol
• Formel: C₂₇H₃₄N₄O₅
• Reinheit: Min. 95%